Answers are grounded in this paper and cite their sources.
Cross-sectional analysis shows plasma and imaging can help estimate amyloid positivity in Alzheimer’s disease, suggesting new biomarker strategies.
Blood-based biomarkers are increasingly used to triage patients for amyloid confirmation, yet performance is often reported versus a single comparator despite discordance between amyloid PET and CSF. In a cross-sectional secondary analysis of the Alzheimer’s Disease Neuroimaging Initiative (ADNI), we assembled one PET-anchored PET–CSF–plasma triad per participant ( n = 320). Bayesian latent class models integrating PET, CSF and plasma (Aβ42/40 or %p-tau217) estimated pattern-level posterior probabilities of latent amyloid positivity, with prespecified sensitivity analyses for PET–CSF conditional dependence, timing gaps (≤7, 8–30, >30 days) and CSF cutpoints. Concordant PET + /CSF+ and PET − /CSF− patterns mapped to probabilities near 1 and 0, whereas discordant patterns yielded intermediate probabilities refined by plasma strata and most sensitive to dependence assumptions. PET–CSF discordance occurred even within ≤7 days (12/98; 12%). A CSF Aβ42 coverage analysis showed similar gradients. Pattern-to-probability reporting may aid interpretation without privileging a reference test.
No takes yet. Share an insight, caveat, or question.
Verma et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: